

## Biosketch



### **Jia Liu, M.D.**

Associate Professor  
Department of Infectious Diseases  
Union Hospital, Tongji Medical College  
Huazhong University of Science and Technology  
Jiefang Avenue 1277, Wuhan 430030, China  
Phone: 0086 186 96159826  
Fax: 027-85356369  
Email: [jjaliu77@hust.edu.cn](mailto:jjaliu77@hust.edu.cn)

He received his M.D. in Immunology from the Huazhong University of Science and Technology, China in 2009. He did his postdoctoral training at the Institute for Virology, University Hospital Essen, Germany from 2009 to 2014. In 2015 he became a PI of the Department of Infectious Diseases, Union Hospital, Tongji Medical college, Huazhong University of Science and Technology. He is currently a member of the Youth Committee of Hepatology study group, the Chinese Medical Association; members Council and Committee of Asia-Pacific Association of Medicine and Bio-Immunology, et al.

His research is focused on immune responses against chronic hepatitis B virus (HBV) infection, with a special emphasis on liver immunity. His goal is to develop novel immunotherapies to overcome HBV persistence. His work is currently supported by the National Natural Science Foundation of China and the National Scientific and Technological Major Project of China. He has published over 70 scientific research papers with many of them in high-impact journals including Journal of Hepatology, PLoS Pathogens, EbioMedicine and Journal of Immunology, et al.

### **Research Project Funded by:**

The National Science and Technology Major Project for Infectious Diseases of China (2017ZX10202203-007-006)

The National Natural Science Foundation of China (M-0060)

The National Natural Science Foundation of China (81861138044)

The National Natural Science Foundation of China (91742114)

### **Selected Publications:**

1. Huang H, Rückborn M, Le-Trilling VTK, Zhu D, Yang S, Zhou W, Yang X, Feng X, Lu Y, Lu M, Dittmer U, Yang D, Trilling M, **Liu J**. Prophylactic and Therapeutic HBV Vaccination by an HBs-expressing Cytomegalovirus Vector Lacking an Interferon Antagonist in Mice. *Eur J Immunol*. 2021 Feb;51(2):393-407.
2. Yang S, Wang L, Pan W, Bayer W, Thoens C, Heim K, Dittmer U, Timm J, Wang Q, Yu Q, Luo J, Liu Y, Hofmann M, Thimme R, Zhang X, Chen H, Wang H, Feng X, Yang X, Lu Y, Lu M, Yang D, **Liu J**. MMP2/MMP9-mediated CD100 shedding is crucial for inducing intrahepatic anti-HBV CD8 T cell responses and HBV clearance. *J Hepatol*. 2019 Oct;71(4):685-698.
3. **Liu J**, Yu Q, Wu W, Huang X, Broering R, Werner M, Roggendorf M, Yang D, Lu M. TLR2 Stimulation Strengthens Intrahepatic Myeloid-Derived Cell-Mediated T Cell Tolerance through Inducing Kupffer Cell Expansion and IL-10 Production. *Journal of Immunology*. 2018 Apr 1;200(7):2341-2351.
4. Wang Q, Pan W, Liu Y, Luo J, Zhu D, Lu Y, Feng X, Yang X, Dittmer U, Lu M, Yang D, **Liu J**. Hepatitis B Virus-Specific CD8+ T Cells Maintain Functional Exhaustion after Antigen Reexposure in an Acute Activation Immune Environment. *Front Immunol*. 2018 Feb 12;9:219.
5. Xu C, Lu Y, Zheng X, Feng X, Yang X, Timm J, Wu J, Wang B, Lu M, Yang D, **Liu J**. TLR2 Expression in Peripheral CD4+ T Cells Promotes Th17 Response and Is Associated with Disease Aggravation of Hepatitis B Virus-Related Acute-On-Chronic Liver Failure. *Front Immunol*. 2017 Nov 23;8:1609.
6. Wu W, Dietze KK, Gibbert K, Lang KS, Trilling M, Yan H, Wu J, Yang D, Lu M, Roggendorf M, Dittmer U, **Liu J**. TLR ligand induced IL-6 counter-regulates the anti-viral CD8(+) T cell response during an acute retrovirus infection. *Sci Rep*. 2015 May 21;5:10501.
7. **Liu J**, Zhang E, Ma Z, Kosinska A, Zhang X, Möller I, Seiz P, Glebe D, Wang B, Yang D, Lu M, Roggendorf M. Enhancing Virus-Specific Immunity In Vivo by Combining Therapeutic Vaccination and PD-L1 Blockade in Chronic Hepadnaviral Infection. *PLoS Pathogens*. 2014 Jan;10(1):e1003856.
8. **Liu J**, Jiang M, Ma Z, Zelinskyy G, Dietze K, Dittmer U, Schlaak J, Roggendorf M, Lu M. TLR1/2 Ligand-Stimulated Mouse Liver Endothelial Cells Secrete IL-12 and Trigger CD8+ T Cell Immunity In Vitro. *Journal of Immunology*. 2013 Dec 15;191(12):6178-90.
9. **Liu J**, Zheng X, Tong Q, Li W, Wang B, Sutter K, Trilling M, Lu M, Dittmer U, Yang D. Overlapping and discrete aspects of the pathology and pathogenesis of the emerging human pathogenic coronaviruses SARS-CoV, MERS-CoV, and 2019-nCoV. *J Med Virol*. 2020 May;92(5):491-494.
10. **Liu J**, Li S, Liu J, Liang B, Wang X, Wang H, Li W, Tong Q, Yi J, Zhao L, Xiong L, Guo C, Tian J, Luo J, Yao J, Pang R, Shen H, Peng C, Liu T, Zhang Q, Wu J, Xu L, Lu S, Wang B, Weng Z, Han C, Zhu H, Zhou R, Zhou H, Chen X, Ye P, Zhu B, Wang L, Zhou W, He S, He Y, Jie S, Wei P, Zhang J, Lu Y, Wang W, Zhang L, Li L, Zhou F, Wang J, Dittmer U, Lu M, Hu Y, Yang D, Zheng X. Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients. *EBioMedicine*. 2020 May;55:102763.
11. Xu L, **Liu J**, Lu M, Yang D, Zheng X. Liver injury during highly pathogenic human coronavirus infections. *Liver Int*. 2020 Mar;40(5):998-1004.
12. Wang S, Trilling M, Sutter K, Dittmer U, Lu M, Zheng X, Yang D, **Liu J**. A Crowned Killer's Résumé: Genome, Structure, Receptors, and Origin of SARS-CoV-2. *Virology*. 2020 Dec;35(6):673-684.

## **Research Group**

**Staffs:**

**MS and MD/PhD Students:**